Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Galera Therapeutics Inc (GRTX)

Galera Therapeutics Inc (GRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,600
  • Shares Outstanding, K 26,822
  • Annual Sales, $ 0 K
  • Annual Income, $ -80,530 K
  • 60-Month Beta 2.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade GRTX with:

Options Overview Details

View History
  • Implied Volatility 395.91% ( +205.46%)
  • Historical Volatility 91.96%
  • IV Percentile 96%
  • IV Rank 58.05%
  • IV High 602.84% on 06/17/22
  • IV Low 109.62% on 04/14/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 69
  • Volume Avg (30-Day) 249
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 6,105
  • Open Int (30-Day) 9,297

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.47
  • Number of Estimates 2
  • High Estimate -0.43
  • Low Estimate -0.50
  • Prior Year -0.88
  • Growth Rate Est. (year over year) +46.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1800 +9.32%
on 07/01/22
1.7600 -26.70%
on 06/06/22
-0.1900 (-12.84%)
since 06/01/22
3-Month
1.1500 +12.17%
on 05/12/22
2.4500 -47.35%
on 04/06/22
-1.0500 (-44.87%)
since 04/01/22
52-Week
1.1500 +12.17%
on 05/12/22
10.7900 -88.04%
on 07/12/21
-8.8000 (-87.22%)
since 07/01/21

Most Recent Stories

More News
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC

Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the...

GRTX : 1.2900 (-0.77%)
Galera to Present at Jefferies Healthcare Conference

MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...

GRTX : 1.2900 (-0.77%)
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and...

GRTX : 1.2900 (-0.77%)
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates

Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 ...

GRTX : 1.2900 (-0.77%)
Galera Announces Plan to Submit Avasopasem NDA by Year End

After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of...

GRTX : 1.2900 (-0.77%)
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...

GRTX : 1.2900 (-0.77%)
Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug Study

Editas (EDIT) doses the first patient pediatric patient in the BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10).

VYGR : 6.08 (+2.88%)
EDIT : 12.59 (+6.42%)
APLT : 0.8650 (-8.77%)
GRTX : 1.2900 (-0.77%)
Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal

Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoint. Stock falls sharply.

VYGR : 6.08 (+2.88%)
APTX : 0.5500 (-1.42%)
APLT : 0.8650 (-8.77%)
GRTX : 1.2900 (-0.77%)
Bristol Myers (BMY) Gets EC Nod for CAR T Cell Therapy Breyanzi

The European Commission grants marketing authorization to Bristol Myers' (BMY) Breyanzi for treating certain forms of relapsed or refractory large b-cell lymphoma.

BMY : 76.84 (-0.21%)
VYGR : 6.08 (+2.88%)
APLT : 0.8650 (-8.77%)
GRTX : 1.2900 (-0.77%)
Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates

Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA...

GRTX : 1.2900 (-0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The company's product candidate is GC4419, a highly selective and potent small molecule dismutase mimetic which...

See More

Key Turning Points

3rd Resistance Point 1.4367
2nd Resistance Point 1.3633
1st Resistance Point 1.3267
Last Price 1.2900
1st Support Level 1.2167
2nd Support Level 1.1433
3rd Support Level 1.1067

See More

52-Week High 10.7900
Fibonacci 61.8% 7.1075
Fibonacci 50% 5.9700
Fibonacci 38.2% 4.8325
Last Price 1.2900
52-Week Low 1.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar